The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Males are more often affected than females. The risk of death with proper treatment is about 5% while without it is around 75%. While cases that appear similar to MH have been documented since the early 20th century, the condition was only formally recognized in 1960.
== Research == Some of Patton's earliest research in collaboration with D. V. Josephson revealed that a change in methionine in milk was responsible for the off flavor produced when milk is exposed to light. In other of his early work Patton discovered that malonic dialdehyde is a product of lipid oxidation and the basic reactant in the thiobarbituric acid and Kreis tests for lipid oxidation. One of the first to use gas chromatography, mass spectrometry and thin layer chromatography in flavor research, Patton proved, using these techniques, that methyl sulfide is a key component in the flavor of milk, methods his student Allen Day, who went on to become vice-president for research at IFF, put to good use. At Penn State, "in the 1960s and 1970s, Patton would lead a departmental redirection into lipid research with important insights on mammary gland milk fat synthesis,” but he attributed the turn in his research from the characterization of milk lipids to milk synthesis and secretions to Robert McCarthy. Patton's research in this area is summarized in Biomedical Aspects of Lactation. While lipid research continued to be a focus of Patton's investigations on the various expeditions he participated on with Andrew Benson, (for example, the importance of triglyceride in the salmon's heart function; the chemical characterization of unique lipids in marine animals), an investigation that demonstrated the high food value of the red tide organism (the phytoplankton bloom), remains under explored.
=== Pathways === Until recently, necrosis was thought to be an unregulated process. However, there are two broad pathways in which necrosis may occur in an organism. The first of these two pathways initially involves oncosis, where swelling of the cells occurs. Affected cells then proceed to blebbing, and this is followed by pyknosis, in which nuclear shrinkage transpires. In the final step of this pathway cell nuclei are dissolved into the cytoplasm, which is referred to as karyolysis. The second pathway is a secondary form of necrosis that is shown to occur after apoptosis and budding. In these cellular changes of necrosis, the nucleus breaks into fragments (known as karyorrhexis).
Sources: en.wikipedia.org
Henry Drysdale Dakin FRS (12 March 1880 – 10 February 1952) was an English chemist. He was born in London as the youngest of 8 children to a family of steel merchants from Leeds. As a school boy, he conducted water analysis with the Leeds City Analyst. He was taught chemistry by Julius B. Cohen at the University of Leeds, and then he worked with Albrecht Kossel on arginase at the University of Heidelberg. He joined Columbia University in 1905, working in the lab of Christian Herter. During his work on amino acids he obtained his PhD from Leeds. In 1905, he was one of the first scientists to successfully synthesise adrenaline in the laboratory (see: History of catecholamine research). In 1914 he went back to England to offer his service with the war effort. Due to a request for a chemist by Alexis Carrel to the Rockefeller Institute, Dakin joined Carrel in 1916 at a temporary hospital in Compiègne. There they developed the Carrel–Dakin method of wound treatments. This consisted of intermittently irrigating the wound with Dakin's solution, a dilute solution of sodium hypochlorite (the active ingredient in common liquid bleach products) and boric acid. In the process, he analyzed more than 200 candidate substances, and developed quantitative methods to evaluate their effectiveness for disinfection and wound healing. The solution is still widely used for that purpose, as of 2013. The World War I era Rockefeller War Demonstration Hospital (United States Army Auxiliary Hospital No. 1) was created, in part, to promote the Carrel–Dakin method:
=== In silico screening === T cell epitope content, which is one of the factors that contributes to the risk of immunogenicity can now be measured relatively accurately using in silico tools. Immunoinformatics algorithms for identifying T-cell epitopes are now being applied to triage protein therapeutics into higher risk and low risk categories. These categories refer to assessing and analyzing whether an immunotherapy or vaccine will cause unwanted immunogenicity. One approach is to parse protein sequences into overlapping nonamer (that is, 9 amino acid) peptide frames, each of which is then evaluated for binding potential to each of six common class I HLA alleles that "cover" the genetic backgrounds of most humans worldwide. By calculating the density of high-scoring frames within a protein, it is possible to estimate a protein's overall "immunogenicity score". In addition, sub-regions of densely packed high scoring frames or "clusters" of potential immunogenicity can be identified, and cluster scores can be calculated and compiled. Using this approach, the clinical immunogenicity of a novel protein therapeutics can be calculated. Consequently, a number of biotech companies have integrated in silico immunogenicity into their pre-clinical process as they develop new protein drugs.
According to the February 1921 census, 3,123,000 native German speakers lived in Czechoslovakia, 23.4% of the total population. The controversies between the Czechs and the German-speaking minority lingered on throughout the 1920s and intensified in the 1930s. During the Great Depression, the mostly-mountainous regions populated by the German minority, together with other peripheral regions of Czechoslovakia, were hurt by the economic depression more than the interior of the country was. Unlike the less developed regions (Carpathian Ruthenia, Moravian Wallachia), the Sudetenland had a high concentration of vulnerable export-dependent industries (such as glass works, textile industry, paper-making and toy-making industry). Sixty percent of the bijouterie and glassmaking industry were located in the Sudetenland, and 69% of employees in the sector were German-speaking according to mother tongue, and 95% of bijouterie and 78% of other glassware was produced for export. The glass-making sector was affected by decreased spending power and by protective measures in other countries, and many German workers lost their work. The high unemployment, as well as the imposition of Czech in schools and all public spaces, made people more open to populist and extremist movements such as fascism, communism and German irredentism. In those years, parties of German nationalists and later the Sudeten German Party (SdP), with its radical demands gained immense popularity, among Germans in Czechoslovakia.
Sources: en.wikipedia.org
Biosynthesis is chemical synthesis occurring in biological contexts. It most often refers to multi-step, enzyme-catalyzed processes where chemical substances absorbed as nutrients (or previously converted through biosynthesis) serve as enzyme substrates, with conversion by the living organism either into simpler or more complex products. Examples of biosynthetic pathways include those for the production of amino acids, lipid membrane components, and nucleotides, but also for the production of all classes of biological macromolecules, and of acetyl-coenzyme A, adenosine triphosphate, nicotinamide adenine dinucleotide and other key intermediate and transactional molecules needed for metabolism. Thus, in biosynthesis, any of an array of compounds, from simple to complex, are converted into other compounds, and so it includes both the anabolism and catabolism (building up and breaking down) of complex molecules (including macromolecules). Biosynthetic processes are often represented via charts of metabolic pathways. A particular biosynthetic pathway may be located within a single cellular organelle (e.g., mitochondrial fatty acid synthesis pathways), while others involve enzymes that are located across an array of cellular organelles and structures (e.g., the biosynthesis of glycosylated cell surface proteins).
=== Second term (2020–2021) === Talarico defeated former Hutto city council member Lucio Valdez with 51.5% of the vote. In the 87th Texas Legislature, he was reappointed to the Public Education and Juvenile Justice Committees and appointed to the Calendars Committee. During the 87th legislative session, Talarico filed HB 54, also known as Javier Ambler's Law, and the legislature passed it. It prohibits state law enforcement agencies, except game wardens, from entering into contracts with reality TV shows that film them in the line of duty. This was in response to the role Live PD is alleged to have played in the killing of Javier Ambler by Williamson County, Texas, police. Talarico had previously criticized Sheriff Robert Chody's handling of the incident, calling for his resignation. Talarico was the primary author of HB 30, which provides a path for minors in the criminal justice system who have been adjudicated as adults or who are eligible under the Individuals with Disabilities Education Act to earn a high school diploma instead of pursuing a high school equivalency. In 2018, Talarico was diagnosed with type 1 diabetes during a five-day stint in the ICU after a campaign event where he walked 25 miles (40 km) across his district. After his diagnosis, he paid $684 for his first 30-day supply of insulin. Talarico later helped pass House Bill 82, capping insulin costs at $25 per month.
== Gene for protein L == The gene for protein L contains five components: a signal sequence of 18 amino acids; a NH2-terminal region ("A") of 79 residues; five homologous "B" repeats of 72-76 amino acids each; a COOH terminus region of two additional "C" repeats (52 amino acids each); a hydrophilic, proline-rich putative cell wall-spanning region ("W") after the C repeats; a hydrophobic membrane anchor ("M"). The B repeats (36kD) were found to be responsible for the interaction with Ig light chains.[2]
==== Pharmacodynamics ==== In the context of pharmacodynamics (how the drug affects the body), the hydrophobic effect is the major driving force for the binding of drugs to their receptor targets. On the other hand, hydrophobic drugs tend to be more toxic because they, in general, are retained longer, have a wider distribution within the body (e.g., intracellular), are somewhat less selective in their binding to proteins, and finally are often extensively metabolized. In some cases the metabolites may be chemically reactive. Hence it is advisable to make the drug as hydrophilic as possible while it still retains adequate binding affinity to the therapeutic protein target. For cases where a drug reaches its target locations through passive mechanisms (i.e., diffusion through membranes), the ideal distribution coefficient for the drug is typically intermediate in value (neither too lipophilic, nor too hydrophilic); in cases where molecules reach their targets otherwise, no such generalization applies.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.